INTRODUCTION
Despite the growth in product approvals, business formation, employment and
capital investment, biotechnology is facing significant challenges. How will
this research-driven business evolve over the next five years? What will be the
contribution of new players to the sectors' quest for innovation and increasing
productivity? This In-Depth Analysis examines the changing dynamics within the
biotechnology sector to 2007.
SCOPE OF THE REPORT
- Benchmarks the top 10 players in the biotech industry and 12 key emerging
players by 2001 sales, operating profits and R&D spend
- Compares forecast revenues of the leading and emerging products, players,
technologies and therapy areas to 2007
- Profiles 12 key emerging companies: Antisoma, British Biotech, CAT, Celera,
HGS, Isis, Millennium, MorphoSys, OGS, Scios, Vertex and XOMA
- 1,3 and 5 year forecasts for key products and total sales for profiled
companies
REPORT HIGHLIGHTS
In 2001, the 10 biotechnology industry leaders posted an 18% increase in
product revenue, to $10,992m. This was mainly driven by Amgen and Genentech,
generating $4,482m and $1,736m, respectively
Therapeutic proteins are likely to maintain the lead, with forecast revenues
of $19,053m in 2007. Amgen's Enbrel will be the top biotech blockbuster, with
forecast sales of $3,200m in 2007. Second to therapeutic proteins will be
antibodies, forecast to generate $7,635m in 2007.
Millennium could replace Celltech in the top 10 biotech firms, with forecast
product revenue of $710m in 2007. Over the next five years, Millennium, Scios
and Isis will be the three leading emerging players in terms of product sales,
with forecast combined revenue of $1,369m.
KEY REASONS TO BUY THIS REPORT
- Benchmark your strategy against key rivals in the biotechnology sector
- Assess the timescale and impact of new biotechnologies on your business
- Realize the importance of intrabiotech alliance networks to business model
evolution
- Identify potential partners within the emerging biotech sector to drive
your portfolio strategy
- Assess the importance of consolidation within the biotechnology sector
View Cart
